Tokyo, Japan –23 June 2016: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) today announces Sosei Corporate Venture Capital Ltd. (hereinafter “Sosei CVC”), the wholly-owned subsidiary of Sosei, has launched “Sosei RMF1 Limited Partnership for Investment” (hereinafter, “Sosei CVC fund”) along with the Organization for Small & Medium Enterprises and Regional Innovation, Japan, Mizuho Bank, Ltd., Mizuho Securities Principle Investment Co. Ltd., and Shinsei Bank, Limited. The Sosei CVC fund is to be established on 23 June 2016 by Sosei CVC in order to invest in regenerative medicine biotechnology venture companies in Japan.
Sosei has expertise and extensive experience in medical research and development (R&D) and in creating chemical compounds that can potentially be used for new medicines. Sosei will establish the Sosei CVC fund to invest in regenerative medicine biotechnology venture companies in order to develop new businesses in the field. Following the introduction of the Act on the Safety of Regenerative Medicine and the Act on Ensuring Quality, Validity and Safety of Drugs and Medical Devices in November 2014, the approval period required before the practical application of regenerative medicine has been reduced. This has created expectations that various new regenerative medicine-related business opportunities will arise in Japan. Utilizing the experience and expertise it has developed through R&D and business activities in the area of pharmaceutical research, Sosei Group will support the growth of life science companies and broadly contribute to improving people’s health and quality of life through the investment activities of the Sosei CVC fund.
About Sosei CVC
Note: This does not impact earnings.